07:00 , Aug 11, 2014 |  BioCentury  |  Strategy

Profusion of exclusions

Express Scripts Holding Co. 's 2015 formulary exclusions offer hope that companies can renegotiate once-excluded drugs back into coverage. But the pharmacy benefits manager appears to be expanding the number of drugs and drug classes...
07:00 , May 12, 2014 |  BC Week In Review  |  Clinical News

Duac clindamycin/benzoyl peroxide regulatory update

GlaxoSmithKline submitted an application to Japan's Ministry of Health, Labor and Welfare (MHLW) for Duac clindamycin/benzoyl peroxide gel to treat acne. The company declined to comment on when it expects a decision in Japan. In...
07:00 , Mar 11, 2013 |  BC Week In Review  |  Clinical News

Duac clindamycin/benzoyl peroxide regulatory update

GlaxoSmithKline's Stiefel Laboratories Inc. subsidiary said the U.K.'s Medicines and Healthcare products Regulatory Agency (MHRA) recommended approval of Duac clindamycin/benzoyl peroxide gel to treat mild to moderate acne vulgaris, particularly inflammatory lesions, in patients ages...
08:00 , Feb 13, 2012 |  BC Week In Review  |  Company News

Valeant Pharmaceuticals, Mylan deal

Valeant divested generic versions of dermatology drugs BenzaClin clindamycin/benzoyl peroxide gel and Efudex fluorouracil cream to Mylan. The deal includes an ANDA for generic BenzaClin to treat acne and a license to manufacture and market...
07:00 , Jul 18, 2011 |  BC Week In Review  |  Company News

Valeant Pharmaceuticals, Sanofi deal

Valeant will acquire Sanofi's Dermik dermatology unit for $425 million in cash. Dermik, which markets therapeutic and aesthetic dermatology products mainly in the U.S. and Canada, had total 2010 revenue of about $240 million. Valeant...
00:18 , Jul 12, 2011 |  BC Extra  |  Company News

Sanofi sells dermatology business to Valeant

Valeant Pharmaceuticals International Inc. (TSX:VRX; NYSE:VRX) acquired the Dermik dermatology unit from Sanofi (Euronext:SAN; NYSE:SNY) for $425 million in cash. Dermik, which markets therapeutic and aesthetic dermatology products mainly in the U.S. and Canada, had...
07:00 , Oct 5, 2009 |  BC Week In Review  |  Company News

Valeant Pharmaceuticals International deal

Valeant bought out the income rights and milestone obligations owed to former shareholders of Dow Pharmaceutical Sciences Inc. for $115 million. Under the deal, Valeant is released from $235 million in milestone obligations for the...
07:00 , Apr 27, 2009 |  BC Week In Review  |  Company News

Stiefel, GlaxoSmithKline deal

GlaxoSmithKline will acquire dermatology company Stiefel for $2.9 billion in cash. Stiefel shareholders are eligible to receive up to $300 million in milestones, and GSK expects to assume $400 million of Stiefel's net debt. GSK...
01:03 , Apr 21, 2009 |  BC Extra  |  Top Story

GSK to acquire Stiefel

GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) will acquire dermatology company Stiefel Laboratories Inc. (Coral Gables, Fla.) for $2.9 billion in cash. Stiefel shareholders are eligible to receive up to $300 million in milestones, and GSK also expects...
07:00 , Mar 16, 2009 |  BC Week In Review  |  Company News

Valeant sales and marketing update

Valeant's Coria Laboratories Ltd. unit launched Acanya clindamycin/benzoyl peroxide in the U.S. to treat acne vulgaris in patients 12 years and older. The price is not disclosed. The combination of clindamycin phosphate 1.2% and benzoyl...